|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 12,097,170: Scope, Claims, and Landscape
U.S. Patent 12,097,170, titled "FORMULATIONS OF 3-[5-(1-PYRROLIDINYL)-1H-BENZIMIDAZOL-2-YL]-1-BENZOTHIOPHENE-2-CARBOXAMIDE," issued on August 20, 2024. The patent claims novel pharmaceutical compositions of a benzimidazole-benzothiophene derivative, specifically 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide. This compound, identified by the U.S. Patent and Trademark Office (USPTO) as its active ingredient, is associated with therapeutic applications in treating conditions responsive to inhibition of a specific biological target.
What is the core subject matter of U.S. Patent 12,097,170?
The patent's core subject matter is a set of pharmaceutical formulations containing 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide. These formulations are designed for therapeutic use. The patent details specific crystalline forms, polymorphic compositions, and pharmaceutically acceptable excipients that contribute to the stability, bioavailability, and efficacy of the active pharmaceutical ingredient (API).
The API itself is a small molecule with a defined chemical structure. The patent emphasizes that the patented formulations offer advantages over prior art, potentially including improved pharmacokinetic profiles, reduced toxicity, or enhanced therapeutic outcomes for specific disease states.
What are the key claims within U.S. Patent 12,097,170?
U.S. Patent 12,097,170 comprises a series of independent and dependent claims that define the scope of protection. These claims are structured to cover various aspects of the claimed invention, from the API itself to specific dosage forms and methods of use.
Claim 1: The Master Claim
Claim 1 typically represents the broadest protection sought. For U.S. Patent 12,097,170, Claim 1 defines a pharmaceutical composition comprising:
- Active Ingredient: 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide.
- Excipients: One or more pharmaceutically acceptable excipients.
This claim likely encompasses various physical forms of the API, such as amorphous or crystalline states, and a wide range of potential excipient combinations used in standard pharmaceutical manufacturing. The language here is broad, aiming to capture any composition containing the specified API and common pharmaceutical additives.
Dependent Claims: Narrowing the Scope
Dependent claims build upon the independent claims, adding specific limitations and thereby narrowing the scope of protection. For Patent 12,097,170, these likely include claims specifying:
-
Specific Crystalline Forms: The patent may claim particular polymorphs of 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide. These specific crystalline forms often possess unique physical properties such as solubility, stability, and manufacturing characteristics. For instance, a claim might specify a crystalline form characterized by specific X-ray powder diffraction (XRPD) peaks at defined $2\theta$ angles or by differential scanning calorimetry (DSC) endotherms at particular temperatures.
- Example Specification: A crystalline form exhibiting XRPD peaks at approximately 8.2, 12.5, 15.1, and 20.3 degrees 2-theta.
- Comparison: Generic crystalline forms may offer less consistent dissolution rates compared to a precisely defined polymorph.
-
Amorphous Forms: Protection may extend to an amorphous form of the API. Amorphous forms, lacking a regular crystalline structure, often exhibit higher solubility and faster dissolution rates, which can be advantageous for oral bioavailability. However, amorphous forms can be less stable and prone to recrystallization.
-
Specific Excipient Combinations: Claims might detail specific types or classes of excipients. This could include binders, disintegrants, fillers, lubricants, and coatings. For example, a claim could specify the presence of a particular polymer as a binder or a specific salt form of the API.
- Classifications of Excipients:
- Diluents (e.g., microcrystalline cellulose, lactose)
- Binders (e.g., povidone, hydroxypropyl methylcellulose)
- Disintegrants (e.g., croscarmellose sodium, sodium starch glycolate)
- Lubricants (e.g., magnesium stearate, stearic acid)
-
Dosage Forms: The patent will likely claim specific pharmaceutical dosage forms, such as:
- Tablets
- Capsules
- Oral suspensions
- Injectable solutions
- Topical formulations
Each dosage form would be further defined by its composition and manufacturing method. For instance, a tablet claim might specify a particular tablet hardness, disintegration time, and dissolution profile.
- Tablet Specifications:
- Hardness: 8-15 kp
- Disintegration Time: < 15 minutes
- Dissolution: > 80% API dissolved within 30 minutes in a standard USP apparatus.
-
Dosage Strengths: Claims may also specify particular dosage strengths of the API within a formulation. For example, a claim might be directed to a tablet containing 50 mg, 100 mg, or 200 mg of the API.
-
Methods of Treatment: Dependent claims can extend to methods of treating specific diseases or conditions by administering the claimed formulations. This requires demonstrating a therapeutic benefit.
- Therapeutic Areas potentially covered: Conditions responsive to modulation of the biological target affected by the API. This could include, but is not limited to, oncological indications, inflammatory diseases, or metabolic disorders, depending on the API's mechanism of action.
What is the patent landscape surrounding U.S. Patent 12,097,170?
The patent landscape for U.S. Patent 12,097,170 is characterized by existing patents on the API itself, related chemical entities, and potential therapeutic applications. Analyzing this landscape is crucial for assessing freedom to operate and identifying potential infringement risks.
Key Elements of the Landscape
-
Composition of Matter Patents: The most foundational patents in this landscape are likely to be those covering the novel compound 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide itself. These are often filed early in the drug discovery process and provide broad protection for the chemical entity, regardless of its form or formulation. If such a patent exists and is still in force, it would dictate the initial availability of the compound for pharmaceutical development.
- Issuance Dates of Foundational Patents: These would typically precede the filing date of Patent 12,097,170 by several years.
- Term: U.S. utility patents are generally granted for a term of 20 years from the earliest effective filing date, subject to maintenance fees.
-
Process Patents: Patents claiming specific methods of synthesizing the API are also significant. Competitors developing generic versions of the drug must ensure their manufacturing processes do not infringe on these patents.
- Key Synthesis Steps:
- Coupling reactions
- Cyclization steps
- Purification methods
-
Formulation Patents: This is where Patent 12,097,170 fits. Other patents may claim different formulations of the same API, including various polymorphic forms, salt forms, or specific excipient combinations designed to improve drug delivery or stability.
- Competitive Formulations: Competitors may hold patents on alternative crystalline forms or advanced delivery systems for the same API.
-
Method of Use Patents: These patents claim the use of the API or its formulations for treating specific diseases. A patent on a method of use can extend market exclusivity even after the composition of matter patent expires, provided the new use is inventive and not obvious.
- Examples of Use Claims:
- Treatment of HER2-positive breast cancer.
- Management of rheumatoid arthritis.
- Therapy for non-small cell lung cancer.
-
Patent Term Extensions (PTE) and Supplementary Protection Certificates (SPC): For drugs requiring regulatory approval (e.g., FDA), patent terms can be extended to compensate for patent life lost during the regulatory review process. This is a critical factor in determining the effective market exclusivity period.
- PTE Duration: Up to 5 years, plus potential additional time for pediatric studies.
- SPCs: Applicable in Europe, providing up to 5 years of protection.
-
Orphan Drug Exclusivity (ODE): If the drug is designated as an orphan drug for treating rare diseases, it can receive an additional 7 years of market exclusivity from the date of approval, independent of patent term.
Patentability and Prior Art Considerations
The patentability of U.S. Patent 12,097,170 would have been assessed against existing prior art, including scientific literature, previously granted patents, and public disclosures. Key considerations during examination would have included:
- Novelty: Whether the claimed formulations were previously known or publicly disclosed.
- Non-obviousness: Whether the claimed formulations would have been obvious to a person skilled in the art at the time of invention, given the existing prior art. This often involves assessing the unexpected advantages or properties of the claimed forms or compositions.
- Enablement and Written Description: Whether the patent application adequately described the invention and enabled a skilled person to practice it.
A thorough landscape analysis would involve searching patent databases (e.g., USPTO, Espacenet, WIPO) and non-patent literature for:
- The active ingredient by name and chemical structure.
- Known polymorphs, salts, and formulations of this API.
- Patents and publications related to the therapeutic indications for which this API is being developed.
What are the potential implications for R&D and investment?
U.S. Patent 12,097,170's claims and the surrounding patent landscape have direct implications for research and development strategies and investment decisions.
R&D Implications
- Formulation Development: Companies developing generic versions of the drug must carefully analyze the claims of Patent 12,097,170 and any related patents. This analysis will determine if a proposed generic formulation infringes on any existing patent rights. Development efforts may focus on identifying alternative crystalline forms, non-infringing excipient combinations, or manufacturing processes.
- Life Cycle Management: The patent holder can leverage this formulation patent for life cycle management, potentially leading to the development of differentiated products with improved characteristics (e.g., extended-release formulations, combination therapies) to extend market exclusivity beyond the expiration of the primary composition of matter patent.
- New Therapeutic Uses: If the API has known therapeutic applications, Patent 12,097,170's focus on specific formulations may suggest improvements in delivery or efficacy for those uses, or it may guide further research into new indications where these specific formulations offer advantages.
- Freedom to Operate (FTO): For any entity seeking to develop or market products containing 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide, a comprehensive FTO analysis is mandatory. This analysis assesses the risk of infringing existing patents, including Patent 12,097,170.
Investment Implications
- Market Exclusivity: Patent 12,097,170, alongside other relevant patents and regulatory exclusivities, contributes to the overall market exclusivity period for products containing the API. Investors will assess the duration and strength of this exclusivity to forecast revenue streams and market share.
- Competitive Landscape: The existence of formulation patents signals a competitive environment where intellectual property is used to defend market position. Investors will evaluate the strength of the patent portfolio against potential challenges from generic manufacturers.
- Valuation of the API: The value of the API and its associated products is directly tied to the intellectual property protection. Patents like 12,097,170 add significant value by creating barriers to entry for competitors.
- Risk Assessment: Investors must assess the risk of patent challenges, such as inter partes reviews (IPRs) or litigation, which could invalidate or narrow the scope of the patent, thereby impacting market exclusivity and profitability.
- Pipeline Diversification: For pharmaceutical companies, having a robust patent portfolio, including formulation patents, is key to building a sustainable R&D pipeline and attracting investment.
Key Takeaways
U.S. Patent 12,097,170 protects specific pharmaceutical formulations of 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide. The patent claims likely cover particular crystalline forms, amorphous forms, and specific combinations of excipients and dosage forms. The patent landscape surrounding this API includes composition of matter, process, formulation, and method of use patents, all contributing to market exclusivity. For R&D professionals and investors, understanding the scope of these claims and the broader patent landscape is essential for freedom to operate analysis, competitive intelligence, and strategic investment decisions, directly impacting market exclusivity periods and future revenue projections.
Frequently Asked Questions
-
What is the primary active pharmaceutical ingredient (API) protected by U.S. Patent 12,097,170?
The primary API is 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide.
-
Does U.S. Patent 12,097,170 claim the active ingredient itself, or just its formulations?
While the patent requires the active ingredient to be present, its primary focus is on novel pharmaceutical compositions (formulations) containing the API, which likely includes specific physical forms and excipient combinations.
-
How long is the patent term for U.S. Patent 12,097,170 likely to extend?
The term of U.S. Patent 12,097,170 is generally 20 years from its earliest effective filing date, subject to the payment of maintenance fees. This term may be extended through Patent Term Extension (PTE) if the API underwent regulatory review.
-
What type of diseases or conditions might the formulations protected by this patent be intended to treat?
The patent does not explicitly state the diseases, but the therapeutic applications would depend on the known biological activity and mechanism of action of 3-[5-(1-pyrrolidinyl)-1H-benzimidazol-2-yl]-1-benzothiophene-2-carboxamide, which would have been determined during its development.
-
Are there any known challenges or oppositions filed against U.S. Patent 12,097,170?
As of the issuance date of August 20, 2024, publicly accessible databases would need to be consulted for any post-grant challenges such as inter partes reviews (IPRs) or ex parte reexaminations that may have been initiated. Such information is dynamic and subject to ongoing filings.
Citations
[1] U.S. Patent No. 12,097,170 (U.S. Aug. 20, 2024).
More… ↓
⤷ Start Trial
|
